FBS contains 1010–1012 EVs per mL. Every EV prep from serum-containing culture is co-isolated with bovine vesicles. If your downstream application requires MSC-specific EVs, the medium choice is not optional.
MSC-derived exosomes and extracellular vesicles are under active development as therapeutic delivery vehicles and biomarkers. The fundamental problem in most EV production workflows is serum contamination: bovine EVs from FBS co-sediment with MSC-derived EVs at every standard ultracentrifugation speed and cannot be removed without compromising yield.
CelliMax MSC1 is a serum-free, chemically defined MSC expansion medium that allows you to expand MSCs at sufficient density before switching to EV conditioning medium — or to run the full expansion in serum-free conditions from the start.
How CelliMax MSC1 fits into an EV production workflow
- Expansion phase: expand MSCs in CelliMax MSC1 to target cell number — high proliferation rate maintained without serum
- Serum-free switch: transition directly to EV-free conditioning medium with no serum withdrawal step — reduced stress response compared to serum-adapted cells
- Scale-up: MSC1 supports growth in multi-layer flasks and can bridge to hollow-fibre bioreactor formats for larger EV volumes
- Downstream clean-up: no bovine EV background — your NTA and cryo-EM data reflect your MSCs, not the medium
Documentation for EV therapeutic development
For groups developing MSC-EVs as an IND-track therapeutic or advanced diagnostic, full material documentation is available for CelliMax MSC1: composition disclosure, TSE/BSE declaration, endotoxin limits, sterility data. GMP-grade supply in powder and liquid formats.
Serum-free expansion, full quality documentation. Request specifications and volume pricing.
English 
Deutsch